We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

VLN:NYSEValens Semiconductor Ltd. Analysis

Data as of 2026-09-15 - not real-time

$1.62

Latest Price

9/10Risk

Risk Level: High

Executive Summary

At $1.62, Valens Semiconductor Ltd. shows a bearish moving-average alignment, with shorter averages beneath longer ones. It has gained 3.2% over the past 30 days. Relative strength is 38.7 — approaching oversold — and the MACD signal is bearish. Watch $1.60 as support and $2.00 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 146.9% above where the shares trade now. Revenue is growing at 6.1% on a -45.2% profit margin.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 55.6%, a beta of 4.14 and a maximum drawdown of 58.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 91 on the fear-greed composite.
Timeframes disagree: the short-term read is sell while the long-term read is hold, conviction 2 out of 10.

Top Market Events

PTK Acquisition VLN delivered earnings and revenue surprises of 0.Yahoo Finance1monValens Semiconductor Ltd.Detailed price information for Valens Semiconductor Ltd VLN-N from The Globe and Mail including charting and trades.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 1.83
  • MACD momentum is negative

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 1.83
  • Analyst targets imply +146.9% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • Negative profit margin of -45.2%
  • Analyst targets imply +146.9% versus the current price
  • Negative return on equity of -30.4%

Key Metrics & Analysis

Financial Health

Revenue Growth6.10%
Profit Margin-45.23%
P/E Ratio-21.1
ROE-30.38%
ROA-15.72%
Debt/Equity8.26
P/B Ratio1.7
Op. Cash Flow$-13935000
Free Cash Flow$-6985250
Industry P/E32.6

Technical Analysis

TrendBearish
RSI38.7
Support$1.60
Resistance$2.00
MA 20$1.75
MA 50$1.77
MA 200$1.83
MACDBearish
VolumeStable
Fear & Greed Index90.84

Valuation

Target Price$4.00
Upside/Downside146.91%
GradeFair
TypeBlend

Risk Assessment

Beta4.14
Volatility55.62%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.